To the full analysis
Crescent Biopharma stock: growth
CBIOGrowth only counts when it reaches the bottom line. That is why revenue, earnings and free cash flow for Crescent Biopharma, Inc. stand side by side here: revenue growing faster than earnings is growth that was bought.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.7%
per year from 2011 to 2025, per share −19.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 1.3% | −6.0% | 7.7% |
| Revenue per share | −45.8% | −37.0% | −19.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $3.81M | −$6.11M | $13.67M |
| 2012 | $15.26M | $3.66M | −$10.79M |
| 2013 | $3.99M | −$10.61M | −$15.62M |
| 2014 | $15.03M | −$11.12M | −$4.49M |
| 2015 | $20.07M | −$12.77M | −$8.51M |
| 2016 | $18.5K | −$31.81M | −$30.44M |
| 2017 | $0 | −$33.28M | −$30.06M |
| 2018 | $0 | −$48.27M | −$43.46M |
| 2019 | $0 | −$54.12M | −$52.13M |
| 2020 | $10.16M | −$51.03M | −$39.31M |
| 2021 | $1.16M | −$63.43M | −$57.5M |
| 2022 | $75K | −$46.69M | −$46.54M |
| 2023 | $10K | −$36.9M | −$34.9M |
| 2024 | $0 | −$48.52M | −$31.11M |
| 2025 | $10.84M | −$153.94M | −$144.45M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.